News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astellas Pharma Inc. (YPH.BE) Halts Development of Anti-Clotting Drug


9/28/2011 6:55:35 AM

Japan's Astellas Pharma said it halted the global development of the experimental anti-clotting drug darexaban maleate, or YM150, after a study raised questions about its role in treating patients with heart problems. The drugmaker said in a statement on Wednesday that it stopped development of the new oral anticoagulant amid increasing competition and after it was unable to find a partner to help it develop the treatment. A midstage clinical study showed earlier this year that the treatment increased bleeding two- to four-fold in patients with acute coronary problems.

Read at Reuters
Read at BusinessWeek
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES